Pub Date : 2022-12-28DOI: 10.37489/0235-2990-2022-67-9-10-55-62
O. V. Muslimova, M. Zhuravleva, O. A. Demidova, G. I. Gorodetskaya, A. V. Shapchenko, E. Sokova
Despite the fact that the incidence of community-acquired pneumonia (CAP) among young people is significantly lower than among older patients, the frequency of hospitalizations for severe CAP among people under 45 years of age remains high. The effectiveness and duration of treatment directly depend on the rationally selected initial empirical antibacterial therapy (ABT).The aim of the study is to analyze the factors influencing the effectiveness of initial empiric antibacterial therapy for CAP in young people in multidisciplinary medical institutions.Materials and methods. The study was designed as a retrospective observational study; it analyzes 105 medical records of young patients with CAP admitted to one of the multidisciplinary hospitals in Moscow from 2017 to 2019.Results. The empiric ceftriaxone + azithromycin ABT regimen (70% of all prescriptions) was ineffective in 13.7% of cases; monotherapy with ceftriaxone (13% of all prescriptions) was ineffective in 57% cases. Severe CAP, acute respiratory failure, systemic inflammatory response syndrome, and exudative pleurisy were diagnosed with significantly higher frequency in the group of patients with ineffective initial empirical ABT. There was no predominance of any comorbid pathology and Charlson Comorbidity Index in groups where the initial ABT was changed and in groups without a change in initial ABT. The microbiological spectrum of CAP pathogens did not significantly differ in young patients between groups with a changed initial empirical ABT and a group without changing initial ABT.Conclusion. The reasons for the ineffectiveness of the initial empirical ABT could be such factors as: underestimation of the risk of the presence of multidrug-resistant pathogens; underestimation of the risk of viral genesis of CAP; underestimation of the severity of CAP, as well as the severity of CAP complications.
{"title":"Retrospective Analysis of the Initial Empirical Antibiotic Therapy Effectiveness for Community-Acquired Pneumonia in Young Individuals in Moscow Multidisciplinary Hospital","authors":"O. V. Muslimova, M. Zhuravleva, O. A. Demidova, G. I. Gorodetskaya, A. V. Shapchenko, E. Sokova","doi":"10.37489/0235-2990-2022-67-9-10-55-62","DOIUrl":"https://doi.org/10.37489/0235-2990-2022-67-9-10-55-62","url":null,"abstract":"Despite the fact that the incidence of community-acquired pneumonia (CAP) among young people is significantly lower than among older patients, the frequency of hospitalizations for severe CAP among people under 45 years of age remains high. The effectiveness and duration of treatment directly depend on the rationally selected initial empirical antibacterial therapy (ABT).The aim of the study is to analyze the factors influencing the effectiveness of initial empiric antibacterial therapy for CAP in young people in multidisciplinary medical institutions.Materials and methods. The study was designed as a retrospective observational study; it analyzes 105 medical records of young patients with CAP admitted to one of the multidisciplinary hospitals in Moscow from 2017 to 2019.Results. The empiric ceftriaxone + azithromycin ABT regimen (70% of all prescriptions) was ineffective in 13.7% of cases; monotherapy with ceftriaxone (13% of all prescriptions) was ineffective in 57% cases. Severe CAP, acute respiratory failure, systemic inflammatory response syndrome, and exudative pleurisy were diagnosed with significantly higher frequency in the group of patients with ineffective initial empirical ABT. There was no predominance of any comorbid pathology and Charlson Comorbidity Index in groups where the initial ABT was changed and in groups without a change in initial ABT. The microbiological spectrum of CAP pathogens did not significantly differ in young patients between groups with a changed initial empirical ABT and a group without changing initial ABT.Conclusion. The reasons for the ineffectiveness of the initial empirical ABT could be such factors as: underestimation of the risk of the presence of multidrug-resistant pathogens; underestimation of the risk of viral genesis of CAP; underestimation of the severity of CAP, as well as the severity of CAP complications.","PeriodicalId":8471,"journal":{"name":"Antibiotics and Chemotherapy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76047729","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-12-28DOI: 10.37489/0235-2990-2022-67-9-10-25-34
M. A. Кirsanova, Y. Krivorutchenko, O. Postnikova, I. Andronovskaja
Creation of synergistic combinations of antifungal and antiseptic agents can be considered as one of the promising strategies for reducing the spread of drug resistance in pathogenic fungi.Aim. The aim of this work was to study the synergistic antifungal activity of amphotericin B (AMB) and antiseptic miramistin (MST) in their combined use to fight against drug-resistant Candida isolates. Material and methods. One AMB-resistant C.albicans strain (MIC 3.1 µg/ml), sensitive to MST, two isolates of C.albicans with different level of resistance to MST and AMB (MIC 1.6–6.3 µg/ml), and one MST-resistant C.lusitaniae isolate susceptible to AMB (MIC 0.4 µg/ml) were studied. Isolates’ susceptibility to AMB and MST alone was determined by broth microdilution method and time–kill assay, respectively. Individual anti-candida activity of test combinations of 0.001% MST with AMB in 10 or 50 µg/ml concentrations was studied using quantitative time–kill assay.Results. A significant decrease in the growth of all the isolates treated with both test combinations of MST and AMB in comparison with individual medication treatment was observed at each time interval studied (15–60 minutes). As part of the combination, MST exhibited significant synergy with AMB in sublethal concentration of 10 µg/ml against all the isolates. Treatment of the fungi with a combination of MST with AMB in 50 µg/ml concentration caused complete inactivation of all the isolates after 30 minutes. Under these conditions, AMB exhibited separate antifungal activity.Conclusion. These findings suggest the possible effective use of miramistin in combination with amphotericin B against multi-drug resistant isolates of the genus Candida.
{"title":"Synergistic Combination of Amphotericin B and Antiseptic Miramistin May Be Effective in the Fight Against Drug-Resistant Isolates of Candida Fungi","authors":"M. A. Кirsanova, Y. Krivorutchenko, O. Postnikova, I. Andronovskaja","doi":"10.37489/0235-2990-2022-67-9-10-25-34","DOIUrl":"https://doi.org/10.37489/0235-2990-2022-67-9-10-25-34","url":null,"abstract":"Creation of synergistic combinations of antifungal and antiseptic agents can be considered as one of the promising strategies for reducing the spread of drug resistance in pathogenic fungi.Aim. The aim of this work was to study the synergistic antifungal activity of amphotericin B (AMB) and antiseptic miramistin (MST) in their combined use to fight against drug-resistant Candida isolates. Material and methods. One AMB-resistant C.albicans strain (MIC 3.1 µg/ml), sensitive to MST, two isolates of C.albicans with different level of resistance to MST and AMB (MIC 1.6–6.3 µg/ml), and one MST-resistant C.lusitaniae isolate susceptible to AMB (MIC 0.4 µg/ml) were studied. Isolates’ susceptibility to AMB and MST alone was determined by broth microdilution method and time–kill assay, respectively. Individual anti-candida activity of test combinations of 0.001% MST with AMB in 10 or 50 µg/ml concentrations was studied using quantitative time–kill assay.Results. A significant decrease in the growth of all the isolates treated with both test combinations of MST and AMB in comparison with individual medication treatment was observed at each time interval studied (15–60 minutes). As part of the combination, MST exhibited significant synergy with AMB in sublethal concentration of 10 µg/ml against all the isolates. Treatment of the fungi with a combination of MST with AMB in 50 µg/ml concentration caused complete inactivation of all the isolates after 30 minutes. Under these conditions, AMB exhibited separate antifungal activity.Conclusion. These findings suggest the possible effective use of miramistin in combination with amphotericin B against multi-drug resistant isolates of the genus Candida.","PeriodicalId":8471,"journal":{"name":"Antibiotics and Chemotherapy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91246024","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-12-28DOI: 10.37489/0235-2990-2022-67-9-10-18-24
V. Gostev, O. Sulian, O. Kalinogorskaya, L. N. Popenko, A. Kruglov, S. Gordeeva, E. V. Nesterova, D. Gladin, N. N. Trophimova, P. Chulkova, I. Ageevets, V. Ageevets, T. Chernenkaya
Lipoglycopeptide antibiotics are semi-synthetic derivatives of glycopeptides and are characterized by a pronounced bactericidal activity against gram-positive pathogens. The aim of the study was comparative assessment of the sensitivity of gram-positive clinical isolates to lipoglycopeptide antibiotics (telavancin, dalbavancin, oritavancin). The following isolates were included in the work: methicillin-resistant Staphylococcus aureus (MRSA, n=780), methicillin-resistant coagulase-negative Staphylococcus spp. (MRCoNS, n=163), and vancomycin-resistant Enterococcus faecium (VREf, n=93). Serial dilutions were used to assess sensitivity with the addition of 0.002% polysorbate 80 to the medium. Lipoglycopeptides showed more pronounced antibacterial activity against MRSA compared to vancomycin, teicoplanin, and daptomycin, and had a MIC₅₀/MIC₉₀ (µg/ml): for telavancin — 0.06 /0.125, for dalbavancin — 0.016/0.06, and for oritavancin — 0.06/0.125. A trend towards an increase in the MIC of lipoglycopeptides and daptomycin was established in MRSA with the MIC of 2 µg/ml for vancomycin, the proportion of which was 13%. For MRCoNS, MIC₅₀ and MIC₉₀ of lipoglycopeptides did not exceed 0.06 µg/ml and 0.125 µg/ml, respectively. Oritavancin showed strong activity against VREf at MIC range of 0.03 µg/ml to 0.5 µg/ml, and at MIC₉₀ of 0.25 µg/ml. Thus, lipoglycopeptide antibiotics are a plausible alternative to vancomycin and daptomycin; they are characterized by pronounced activity and can be used to treat severe forms of staphylococcal infections.
{"title":"Comparative Activity of Lipoglycopeptide Antibiotics Against Gram-Positive Bacteria","authors":"V. Gostev, O. Sulian, O. Kalinogorskaya, L. N. Popenko, A. Kruglov, S. Gordeeva, E. V. Nesterova, D. Gladin, N. N. Trophimova, P. Chulkova, I. Ageevets, V. Ageevets, T. Chernenkaya","doi":"10.37489/0235-2990-2022-67-9-10-18-24","DOIUrl":"https://doi.org/10.37489/0235-2990-2022-67-9-10-18-24","url":null,"abstract":"Lipoglycopeptide antibiotics are semi-synthetic derivatives of glycopeptides and are characterized by a pronounced bactericidal activity against gram-positive pathogens. The aim of the study was comparative assessment of the sensitivity of gram-positive clinical isolates to lipoglycopeptide antibiotics (telavancin, dalbavancin, oritavancin). The following isolates were included in the work: methicillin-resistant Staphylococcus aureus (MRSA, n=780), methicillin-resistant coagulase-negative Staphylococcus spp. (MRCoNS, n=163), and vancomycin-resistant Enterococcus faecium (VREf, n=93). Serial dilutions were used to assess sensitivity with the addition of 0.002% polysorbate 80 to the medium. Lipoglycopeptides showed more pronounced antibacterial activity against MRSA compared to vancomycin, teicoplanin, and daptomycin, and had a MIC₅₀/MIC₉₀ (µg/ml): for telavancin — 0.06 /0.125, for dalbavancin — 0.016/0.06, and for oritavancin — 0.06/0.125. A trend towards an increase in the MIC of lipoglycopeptides and daptomycin was established in MRSA with the MIC of 2 µg/ml for vancomycin, the proportion of which was 13%. For MRCoNS, MIC₅₀ and MIC₉₀ of lipoglycopeptides did not exceed 0.06 µg/ml and 0.125 µg/ml, respectively. Oritavancin showed strong activity against VREf at MIC range of 0.03 µg/ml to 0.5 µg/ml, and at MIC₉₀ of 0.25 µg/ml. Thus, lipoglycopeptide antibiotics are a plausible alternative to vancomycin and daptomycin; they are characterized by pronounced activity and can be used to treat severe forms of staphylococcal infections.","PeriodicalId":8471,"journal":{"name":"Antibiotics and Chemotherapy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84523745","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-12-27DOI: 10.37489/0235-2990-2022-67-9-10-4-10
O. Efremenkova, I. A. Malanicheva, B. Vasileva, T. A. Efimenko, A. A. Glukhova, O. Kisil, M. V. Demiankova, H. S. Semizaev, N. Gabrielyan
Medicinal probiotic Sporobacterin is based on the Bacillus subtilis 534 strain, which has been shown to have antimicrobial activity against many bacteria, both the collection strains and the antibiotic-resistant forms of clinical isolates of pathogenic bacteria and fungi. Considering this strain as an antibiotic producer, a step-by-step mutagenic treatment was carried out in order to obtain a variant that consistently exhibits a certain high-level antibiotic activity. A mutant variant was obtained during the three stages of mutagenic treatment and selection; it effectively suppresses the growth of pathogenic staphylococci, including methicillin-resistant staphylococcus (MRSA).
{"title":"Induction and Stabilization of Antibacterial Activity in a Bacillus subtilis 534 Probiotic Strain","authors":"O. Efremenkova, I. A. Malanicheva, B. Vasileva, T. A. Efimenko, A. A. Glukhova, O. Kisil, M. V. Demiankova, H. S. Semizaev, N. Gabrielyan","doi":"10.37489/0235-2990-2022-67-9-10-4-10","DOIUrl":"https://doi.org/10.37489/0235-2990-2022-67-9-10-4-10","url":null,"abstract":"Medicinal probiotic Sporobacterin is based on the Bacillus subtilis 534 strain, which has been shown to have antimicrobial activity against many bacteria, both the collection strains and the antibiotic-resistant forms of clinical isolates of pathogenic bacteria and fungi. Considering this strain as an antibiotic producer, a step-by-step mutagenic treatment was carried out in order to obtain a variant that consistently exhibits a certain high-level antibiotic activity. A mutant variant was obtained during the three stages of mutagenic treatment and selection; it effectively suppresses the growth of pathogenic staphylococci, including methicillin-resistant staphylococcus (MRSA).","PeriodicalId":8471,"journal":{"name":"Antibiotics and Chemotherapy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-12-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72780495","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-11-29DOI: 10.37489/0235-2990-2022-67-9-10-35-41
N. Kartashova, A. Ivanina, E. Glubokova, I. N. Falynskova, A. Poromov, I. Leneva
Interferons (IFN) have antiviral activity against many viruses, including the SARS-CoV-2. A combination of IFN-a2b and the antioxidant taurine is widely used in the Russian Federation, and its antiviral activity has not been studied before. The aim of this study was to determine the antiviral activity of interferon drugs, in combination with taurine and without it. The study included cytotoxicity and antiviral activity assays of IFN-a2b preparations, when stored according to the instructions at 2–8°C, and after 1 month storage at temperature 20–26 ° C in a pre-opened state. The combination of IFN alpha-2b with taurine has a higher antiviral activity compared to IFN alpha-2b mono-preparation by more than 25% at a «low» and 85% at a «high» multiplicity of infection. Selectivity index for combinations of IFN-a2b (50,000 IU/dose) + taurine (1 mg/ml) and IFN-a2b (10,000 IU/ml) + taurine (0.8 mg/ml) was more than 600 units, whereas for the IFN-a2b (10,000 IU/ml) it was 200 units. The antiviral activity does not change after one month at room temperature. The combination of interferon with taurine at high concentrations was less toxic than interferon. The results obtained demonstrate practicability of interferon alpha-2b and taurine combination use for treatment and prevention of COVID-19.
{"title":"Antiviral Activity of Interferon alfa-2b and Taurine Combination Against SARS-CoV-2 in vitro","authors":"N. Kartashova, A. Ivanina, E. Glubokova, I. N. Falynskova, A. Poromov, I. Leneva","doi":"10.37489/0235-2990-2022-67-9-10-35-41","DOIUrl":"https://doi.org/10.37489/0235-2990-2022-67-9-10-35-41","url":null,"abstract":"Interferons (IFN) have antiviral activity against many viruses, including the SARS-CoV-2. A combination of IFN-a2b and the antioxidant taurine is widely used in the Russian Federation, and its antiviral activity has not been studied before. The aim of this study was to determine the antiviral activity of interferon drugs, in combination with taurine and without it. The study included cytotoxicity and antiviral activity assays of IFN-a2b preparations, when stored according to the instructions at 2–8°C, and after 1 month storage at temperature 20–26 ° C in a pre-opened state. The combination of IFN alpha-2b with taurine has a higher antiviral activity compared to IFN alpha-2b mono-preparation by more than 25% at a «low» and 85% at a «high» multiplicity of infection. Selectivity index for combinations of IFN-a2b (50,000 IU/dose) + taurine (1 mg/ml) and IFN-a2b (10,000 IU/ml) + taurine (0.8 mg/ml) was more than 600 units, whereas for the IFN-a2b (10,000 IU/ml) it was 200 units. The antiviral activity does not change after one month at room temperature. The combination of interferon with taurine at high concentrations was less toxic than interferon. The results obtained demonstrate practicability of interferon alpha-2b and taurine combination use for treatment and prevention of COVID-19.","PeriodicalId":8471,"journal":{"name":"Antibiotics and Chemotherapy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76226828","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-11-18DOI: 10.37489/0235-2990-2022-67-7-8-82-96
E. N. Olsufyeva, V. Yankovskaya, N. Dunchenko
{"title":"Overview of the Risks of Antibiotic Contamination of Dairy Products","authors":"E. N. Olsufyeva, V. Yankovskaya, N. Dunchenko","doi":"10.37489/0235-2990-2022-67-7-8-82-96","DOIUrl":"https://doi.org/10.37489/0235-2990-2022-67-7-8-82-96","url":null,"abstract":"","PeriodicalId":8471,"journal":{"name":"Antibiotics and Chemotherapy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84244390","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-11-18DOI: 10.37489/0235-2990-2022-67-7-8-71-81
N. Petrova, A. Emelyanova, A. L. Kovalchuk, S. Tarasov
{"title":"The Role of MHC Class I and Class II Molecules in Antibacterial Immunity and Treatment of Bacterial Diseases","authors":"N. Petrova, A. Emelyanova, A. L. Kovalchuk, S. Tarasov","doi":"10.37489/0235-2990-2022-67-7-8-71-81","DOIUrl":"https://doi.org/10.37489/0235-2990-2022-67-7-8-71-81","url":null,"abstract":"","PeriodicalId":8471,"journal":{"name":"Antibiotics and Chemotherapy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81176215","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-11-17DOI: 10.37489/0235-2990-2022-67-7-8-51-56
H. Bazmamoun, V. Bahrami, G. Kalvandi, A. Moradi, M. Eslamian, I. Shahramian, F. Parooie
{"title":"Evaluation of Helicobacter pylori Infection in Asthmatic Children and Its Relationship With Severity of the Disease","authors":"H. Bazmamoun, V. Bahrami, G. Kalvandi, A. Moradi, M. Eslamian, I. Shahramian, F. Parooie","doi":"10.37489/0235-2990-2022-67-7-8-51-56","DOIUrl":"https://doi.org/10.37489/0235-2990-2022-67-7-8-51-56","url":null,"abstract":"","PeriodicalId":8471,"journal":{"name":"Antibiotics and Chemotherapy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-11-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81846063","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-11-17DOI: 10.37489/0235-2990-2022-67-7-8-57-60
L. Temmoeva, E. Galaeva, Z. A. Kambachokova, Z. Alieva, N. M. Temmoev, Z. K. Akaev, M. K. Dzhabrailova, A. A. Kambachokova
{"title":"Methods of Rehabilitation Treatment in Children with Delayed Psychoverbal Development Within The Autism Spectrum","authors":"L. Temmoeva, E. Galaeva, Z. A. Kambachokova, Z. Alieva, N. M. Temmoev, Z. K. Akaev, M. K. Dzhabrailova, A. A. Kambachokova","doi":"10.37489/0235-2990-2022-67-7-8-57-60","DOIUrl":"https://doi.org/10.37489/0235-2990-2022-67-7-8-57-60","url":null,"abstract":"","PeriodicalId":8471,"journal":{"name":"Antibiotics and Chemotherapy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-11-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84134592","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-11-17DOI: 10.37489/0235-2990-2022-67-7-8-61-70
B. Andryukov, N. Besednova, T. Zaporozhets
{"title":"Microplastics and Their Role in the Maintenance and Spread of Antibiotic Resistance Genes in Marine Ecosystems","authors":"B. Andryukov, N. Besednova, T. Zaporozhets","doi":"10.37489/0235-2990-2022-67-7-8-61-70","DOIUrl":"https://doi.org/10.37489/0235-2990-2022-67-7-8-61-70","url":null,"abstract":"","PeriodicalId":8471,"journal":{"name":"Antibiotics and Chemotherapy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-11-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89433279","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：